Navigation Links
Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer
Date:8/24/2009

SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Orexigen((R)) Therapeutics, Inc. (Nasdaq: OREX) today announced that Mark Booth has joined the Company as Chief Commercial Officer. Mr. Booth brings over 25 years of commercial and business development experience to Orexigen. Most recently he served as President of Takeda Pharmaceuticals North America (TPNA) where he presided over the commercial, medical and scientific affairs, business development and all support functions. Under his leadership TPNA became one of the fastest growing pharmaceutical companies in the U.S. with sales of over $4 billion. Over the course of his career Mr. Booth has played an integral role in numerous co-development/co-promotional partnerships including Prevacid((R)), Enbrel((R)) and Actos((R)) which all achieved multi-billion dollar sales status.

"We believe that Contrave((R)), if approved, has the potential to dramatically impact the treatment of obesity. Mark's broad commercial experience and proven track record in many large markets make him a valuable addition to the Orexigen management team as we build our plans for market success," said Michael Narachi, President and Chief Executive Officer. "This is an exciting time for Orexigen and Mark's extensive commercial and partnership experience will be critical as we plan for the Contrave launch and evaluate potential commercial partners."

Prior to his role at TPNA, Mr. Booth served as Senior Vice President, General Manager at Immunex Corporation where he was responsible for the sales, marketing and project management functions until the company was acquired by Amgen in 2002. Prior to his appointment at Immunex Corporation Mr. Booth was at Abbott Laboratories where he served in a range of leadership positions. In his last role he held the title of Division Vice President, General Manager for the $1 billion anti-infective franchise.

Mr. Booth holds a BS in Biology from Northern Illinois University and an MBA from Northwestern University Kellogg School of Management.

About Orexigen((R)) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave((R)), has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product candidate, Empatic(TM), is in the later stages of Phase 2 clinical development, with results expected in the second half of 2009. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found athttp://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference
2. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
3. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
4. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
5. Orexigen(R) Therapeutics to Present at Upcoming Meetings
6. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
7. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
8. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
9. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
10. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
11. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... Adimarket, a ... and approved SVF closed system kit using EmCyte technology, and is expected to be ... to process adipose tissue and obtain stromal vascular fraction (SVF) in a closed environment. ...
(Date:5/31/2016)... ... May 30, 2016 , ... Doctors in Italy say ... live longer than patients with lower levels. Surviving Mesothelioma has just posted an article ... at cancer centers in Genoa and La Spezia, Italy tested the blood serum, tumors, ...
(Date:5/27/2016)... , ... May 27, 2016 , ... PBI-Gordon Corporation is ... and Ornamental Products. , In his 15-year career with PBI-Gordon, Dave has served in ... where he was integral in the development and launch of many of PBI-Gordon’s most ...
(Date:5/26/2016)... and READING, England , ... ( http://www.indegene.com ), a leading global provider of ... pharmaceutical and healthcare organisations and TranScrip ( http://www.transcrip-partners.com ... support throughout the product lifecycle, today announced the ... of IntraScience.      (Logo: http://photos.prnewswire.com/prnh/20141208/720248 ...
Breaking Biology Technology:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):